Summary Photodynamic therapy (PDT) using Photofrin was used in combination with a hypoxic toxin (mitomycin C, MMC) to treat four patients with recurrent skin metastasis of a mammary carcinoma. In precinical experiments an additive effect was found for the combination of MMC and PDT for treating subcutaneous RIFI tumours in mice. When interstitial PDT was combined with a low dose of MMC (administered 15 min before illumination), the Photofrin dose or light dose could be reduced by a factor of 2 in order to obtain equivalent cure rate or growth delay. In the clinical pilot study, a low dose of Photfrin (0.75 mg kg-') was used for PDT alone (superficial illumination) or combined with low-dose MMC (5 mg m-2). Different tumour areas were illuminated with or without a preceding infusion of MMC. Both tumour response and skin photosensitivity were scored. After 8-12 weeks of treatment, tumour cure could be achieved by administering light doses > 150 J cm-2 for PDT alone and similar effects were obtained when light doses of 75-87.5 J cm-2 were given after infusion with MMC. In all cases necrotic tissue of both tumour and surrounding skin was observed, which lasted for a mean of 5 months (range 2-20 months). Skin phototoxicity, tested by using a standardised illumination of skin patches on the back, lasted maximally 3 weeks. Three main conclusions could be drawn from these studies: (1) The enhanced effects of the combination of PDT and MMC observed in mouse tumours can be extrapolated to patients with mammary skin metastasis. (2) The combination of PDT and hypoxic toxins facilitates treatment by permitting lower doses of photosensitiser to be used (thereby reducing skin phototoxicity) or lower light doses (thereby reducing illumination times and allowing the possibility to treat larger tumour areas). (3) Restoration of skin after PDT in previously treated tumour areas (chemotherapy, radiation therapy and surgery) is very slow.
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Keywords: photodynamic therapy; mitomycin C; bioreductive drugs; mammary carcinoma Photodynamic therapy is now becoming a more accepted form of treatment for small superficial tumours. Its major advantage is the relatively selective treatment of tumours with preservation of the surrounding normal tissue. Preferential retention of the photosensitiser by the tumour tissue and selective illumination are the cornerstones in this treatment. To obtain total tumour eradication, the light used to excite the photosensitiser must penetrate the full depth of the tumour tissue (Ben Hur et al., 1987) and sufficient photosensitiser and oxygen must be available for the formation of highly reactive singlet oxygen. Direct tumour cell kill may arise from this process but vasculature effects will also lead to hypoxia. If the hypoxia is deep and long lasting enough, additional tumour cells will be killed as a consequence of this hypoxia (Henderson et al., 1985; Star et al., 1986) . Subcurative treatment, leading to recurrence of tumour can therefore be the result of inadequate light penetration, a lack of oxygen or low sensitiser dose. Tumour tissue is often not optimally vascularised and areas of hypoxia have been observed by many investigators, not only in animal models but also in human tumour tissues. The photochemical reaction itself will also consume oxygen and this can lead to an oxygen deficit during prolonged illumination, even when the vasculature is intact (Foster et al., 1993) . It is therefore believed that an important limitation in successful PDT is the lack of oxygen. Several studies have been directed to overcome this problem by techniques that can replace or increase the oxygen content in the tumour, e.g. addition of carbogen (Fingar et al., 1988) or by increasing tumour blood flow (Foster et al., 1993; Cowled and Forbes, 1989 ). An alternative approach is to exploit the PDT-induced hypoxia by the addition of a hypoxic toxin which will specifically target cells at low oxygen tensions (Baas et al., 1993; Bremner et al., 1990 Bremner et al., , 1992 Cho et al., 1992; Gonzalez et al., 1986) .
Breast cancer is the most common cancer in females in all industrialised countries. Although the initial treatment of breast cancer is very successful, many patients are at risk of developing a recurrence in the course of their disease. Distant metastasis will be found in approximately half of the patients and 5-10% will suffer from local residual or recurrent disease. Local recurrences are treated with various modalities, such as surgery, hormonal or chemotherapy or radiation therapy. In spite of these treatments, some patients will still suffer from residual disease and complain initially of the cosmetic changes. If left untreated, ulceration and pain will become a serious risk. For these patients, photodynamic therapy could be an alternative treatment and it has been shown to be feasible by Kahn et al. (1993 ), Schuh et al. (1987 and Sperduto et al. (1991) .
The major side-effect of PDT using Photofrin is skin phototoxicity since the injected photosensitiser is also retained by the skin. Sensitivity for intense light can last from 8 to 12 weeks after standard Photofrin doses of 2 mg kg-'. A reduction in the duration of skin phototoxicity can be obtained by decreasing the photosensitiser dose (Wilson et al., 1992) . However, since the photochemical process is then less efficient, illumination times have to be increased (Kahn et al., 1993 (Baas et al., 1993) . The diffusing tip was inserted through the centre of the tumour. To avoid hyperthermal effects, the light fluence rate was fixed at 100 mW cm-'. The energy deposition varied from 100 to 400 J cm-'.
Superficial photodynamic treatment Superficial illumination of normal skin of mice was given by a cold light lamp (type KL 1500, Scott, Mainz, Germany, emission spectrum 300-700 nm) fitted with a 150 W halogen lamp (Osram, The Netherlands). A fluence rate of 200 mW cm-2 was used to deliver energies of 0-150 J cm-2 to skin patches of 2.5 cm2 in a maximum illumination time of 12.5 min as described previously (Baas et al., 1994 
Skin phototoxicity
The extent of skin phototoxicity induced by this low dose of Photofrin was determined using the method described by Baas et al. (1995) . Skin patches of 2.5 cm2 on the normal skin of the back were illuminated weekly after administration of the photosensitiser. The energy applied to the skin patches varied from 10-50 J cm-2 (fluence rate 150 mW cm-2). After 1 h the induced erythema was measured using a Minolta Chroma Meter (type CR-200, Minolta Camera, Osaka, Japan) and by visual scoring.
Results

Preclinical results
Previous published results had demonstrated that Photofrinmediated PDT was enhanced by MMC given before illumination when high doses of both photosensitiser (10 mg kg-') and MMC (5 mg kg-') were given (Baas et al., 1994 ). New studies demonstrate that the enhanced effect is still seen using lower doses of either photosensitiser (5 mg kg-') or MMC (2.5 mg kg-'). All the combined treatments gave longer tumour regrowth times (Table I) and more cures (Table II) than PDT alone or MMC alone (P<0.0001). Tumour regrowth times decreased significantly (P<0.0001) when PDT was given with low doses of Photofrin (5 mg kg-') instead of the standard Photofrin dose of 10 mg kg-'. The maximum effect was obtained using high doses of both drugs but the regrowth times and TCD50 values (light dose required for 50% tumour cure) for 2.5 and S mg kg-' MMC with the high photosensitiser dose were not significantly different.
The mouse skin phototoxicity scoring system as described by Baas et al. (1995) was used to evaluate the combination of Photofrin (10 mg kg-', given 1 day before illumination) and MMC (5 mg kg-', given 15 min before illumination). Using the visible scoring system it was possible to obtain reproducible profiles for skin damage. The mean skin reactions for different light doses given 1 day after injection of Photofrin with or without MMC are shown in Figure la . A slight increase in mean skin reaction was observed when PDT was combined with MMC given 15 min before illumination. A light dose of 75 J cm-2 in combination with MMC produced as much skin damage as 90 J cm-2 PDT alone. MMC given 24 h before illumination did not increase skin reactions relative to PDT alone (data not shown). In order to compare skin reactions quantitatively after PDT, a light dose response curve was constructed for the incidence of dry and moist desquamation. Only animals with at least 25% of the illuminated area developing desquamation were scored as 'responders'. calculations. This analysis demonstrated no significant difference in the incidence of desquamation response between PDT alone or in combination with MMC (light doses of 49.0+6.3 and 57.0+7.9 J cm-2 gave a response in 50% of the mice).
Clinical results
Four patients were entered in the pilot study in a 2 year period. The patient characteristics are presented in Table III . All had previous treatments for their recurrent mammary metastases. The major complaints at time of PDT were progression of the tumours and the resultant cosmetic appearance. All patients were treated according to the protocol, and three patients fulfilled all inclusion criteria, including positive cytology. The fourth patient experienced progression of the lesions but the repeated cytological examination was negative (insufficient material). In all patients a predictable course of tumour reaction was observed: no direct change of the tumour during the light treatment but a brown-bluish discolouration which developed after 24 h (Figure 2 ). Over the next 10 days the lesion turned into a dry black scab which was present for at least 8 weeks. Areas treated with light doses of > 150 J cm-2 (PDT alone) or some areas treated with 75-88 J cm-2 in combination with MMC, had scabs lasting 8-20 months (Figure 3) . In most treated tumour areas, normal skin reappeared after the scab had fallen off. In patient 1, skin metastases were also located on the back and treated according to the protocol. The scabs resolved soonest in these illuminated areas with perfect healing of the skin. In 3 of the 19 lesions treated an exudative local infection developed, two could be treated locally but one required a course of oral antibiotics. One treatment session was complicated by a burning sensation 14 min after the start of the treatment (administered dose: 128 J cm-2). Further treatment was delayed for 24 h and no change occurred in the treated area. Further illumination procedures were uneventful. One patient died 4 months after treatment owing to newly diagnosed bone metastasis in the The treated area shows discoloration and slight swelling. 
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Photodynamic therapy by mitomycin C P Baas et a! Photofrin (data derived from a lung cancer patient treated with PDT, Baas et al., 1995) . All patients were advised to avoid direct sunlight for 2 weeks after injection and then gradually expose their skin. No side-effects were experienced by the patients and normal activity could be resumed within 2-3 weeks.
Discussion
Chronic tumour hypoxia, owing to pronounced PDT-induced vascular damage, is considered to be one of the major mechanisms whereby PDT kills tumour cells in vivo (Henderson et al., 1985; Reed et al., 1988) . Various laboratory investigators have therefore explored the approach of combining bioreductive drugs with photodynamic therapy in order to exploit the PDT-induced hypoxia and enhance the tumoricidal effect of the bioreductive drug (Evensen and Moan, 1988; Gonzalez et al., 1986; Winther et al., 1988; Bremner et al., 1992; Baas et al., 1994; Van Geel et al., 1995) . In most cases an advantage was observed for the combination therapy although exact timing of the administration of the bioreductive drug appeared to be important (Evensen and Moan, 1988; Winther et al., 1988) .
In the present preclinical and clinical study we chose MMC as the bioreductive drug to be combined with PDT despite its relatively low oxic/hypoxic ratio of 2 to 3 (concentration of drug necessary to kill equal amounts of tumour cells in aerobic conditions vs hypoxic conditions). The reasons for this choice were that this drug is a wellestablished clinical cytotoxic drug with limited or no sideeffects in a single administered dose of 5 mg m-2 and that our previous preclinical experiments indicated that the combination of MMC with PDT was effective.
The mouse tumour experiments described in this study clearly show an enhanced effect of the combination of Photofrin-mediated PDT and MMC. This effect was observed both for a standard (high) dose of Photofrin and MMC and for reduced doses of photosensitiser and MMC. The skin phototoxicity in mice increased slightly for the groups treated with both PDT and MMC in the higher light doses when MMC was given 15 min before illumination. Lower light doses did not show an increase in skin sensitivity in the combination group. There was no enhanced skin phototoxicity when MMC was given 24 h before illumination. The clinical importance of this enhanced skin phototoxicity is therefore limited since it is of short duration.
To our knowledge this is the first clinical attempt to study the combination of PDT with a bioreductive drug. From this study of only four patients, no definitive conclusions can be made. It appears, however, that superficial skin metastasis can be treated with PDT alone or in combination with MMC and lower light doses. The energy required to obtain a complete response with PDT alone varied between 150 J cm-2 and 175 J cm-2 and is probably related to the tumour volume and depth or, to a lesser extent, drug distribution in the tumour. Large areas (>100 cm2) are difficult to treat because adequate illumination with the currently available lasers and fibres is too time-consuming. One of the major problems encountered was the difficulty in measuring the exact tumour thickness. Most lesions tended to recur at later times (> 12 months), and we feel that the The addition of MMC given before illumination allowed us to reduce the energy by a factor of approximately 2 and still achieve the same tumour response. Of the seven tumour areas treated with combined MMC and PDT only two failed to achieve a complete response. These results seem to confirm the enhanced effect of MMC and PDT we observed in the mouse tumour model. All patients tolerated the combined treatment without sequelae. Although we did not investigate the effect of a single dose of MMC alone on mammary skin metastases, it is not expected that this low single dose would significantly influence the growth rate in the absence of PDT. Timing of the injection of mitomycin C with respect to the illumination appears to be important since the pharmacokinetic profile indicates that after 20 and 40 min only 60% and 25% of the drug remains in the serum, respectively. Whether this reflects the actual activity is uncertain since the drug has to diffuse through the tumour tissue and is cleared by the liver. The calculated half-life in the three patients lies within the expected range of 10-50 min according to the maximum plasma concentration (Crooke and Bradner, 1976; Verweij and Pinedo, 1990) . Preclinical studies in other laboratories are currently investigating whether the effect of MMC is indeed due to a bioreductive effect or if other processes are involved, such as enhanced uptake of the Photofrin in MMCtreated cells or changes in cell cycle which renders the tumour cells more sensitive for PDT (Ma et al., 1993) .
With regard to the skin phototoxicity, patients showed an increased sensitivity for the test doses of light immediately after injection of low dose (0.75 mg kg-') Photofrin. This lasted for 2-3 weeks as measured by the reflectance meter. Normal outdoor activity could be resumed in the third week after injection. These results are in clear contrast with the normal skin photosensitivity encountered after the standard advised dose of 2 mg kg-' of Photofrin, which lasts 4-12 weeks (Baas et al., 1995; Dougherty et al., 1990; Wilson et al., 1986) . The risk of treating patients with a low dose of Photofrin could be the increased incidence of local tumour recurrences owing to inadequate singlet oxygen production or vessel damage. These recurrences of tumour metastasis were indeed observed in our pilot study.
The conclusions that can be drawn from these studies are: (1) The combination of a hypoxic toxin (MMC) and Photofrin-mediated PDT increased the tumoricidal effect in a mouse tumour model and in patients with mammary skin metastasis. This allows a reduction of light dose and/or photosensitiser dose. (2) Skin photosensitivity was markedly less after low doses of Photofrin than after the standard recommended dose of 2 mg kg-'.
(3) Healing of the induced scabs was very slow in these previously pretreated patients.
(4) Using this low sensitiser dose (0.75 mg kg-' Photofrin) 
